SCHEMBL1708164

SCHEMBL1708164

COC(=O)C[C@@H]1COc2cc(NCc3cccc(-n4c(OC)nc5ccccc54)c3C)ccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 7/20 0.37
GAA P10253 2/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 2/20 0.35
MAPK1 P28482 1/20 0.35
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
NPC1 O15118 2/20 0.34
LMNA P02545 1/20 0.34
ALOX5 P09917 1/20 0.34
PKM P14618 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HTT P42858 1/20 0.34
PDCD1 Q15116 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
PPARD Q03181 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1708621 0.94 FFAR1 (0.43) FFAR1PPARGPPARAPPARD
SCHEMBL1708113 0.93 FFAR1 (0.40) FFAR1GAAPOLBTSHRMAPK1
SCHEMBL10291337 0.92 TSHR (0.39) FFAR1GAAPOLBTSHRMAPK1
SCHEMBL1708157 0.91 FFAR1 (0.38) FFAR1GAAPOLBTSHRMAPK1
SCHEMBL1708074 0.90 ALDH1A1 (0.36) FFAR1GAAPOLBTSHRMAPK1
SCHEMBL1708146 0.90 FFAR1 (0.36) FFAR1GAAPOLBTSHRMAPK1
SCHEMBL1708632 0.90 FFAR1 (0.36) FFAR1GAATSHRMAPK1NPC1
SCHEMBL1708614 0.89 LMNA (0.39) FFAR1TSHRMAPK1PPARGLMNA
SCHEMBL1708013 0.87 FFAR1 (0.47) FFAR1PPARGPPARAPPARD
SCHEMBL1708151 0.86 FFAR1 (0.40) FFAR1GAAPOLBPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
EP-2440541-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-04-18 EP disclosed
WO-2010143733-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-16 WO disclosed
WO-2010143733-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF GPR119, INSR, GLP1R FFAR1 20/4885GAA 3185/4885POLB 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.